Clinical Trials Browser

Ramucirumab × Thoracic × 30 days × Clear all

NCT05062980 2026-06-03

Acclaim-2

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT05642572 2026-06-03

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04310007 2026-05-29

Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

Phase 2 Active not recruiting

Lung Neoplasms

NCT07098338 2026-05-27

LIBRA

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT03527108 2026-05-22

Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT07603856 2026-05-22

REVIVE

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05096663 2026-05-18

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms